Lexicon Selling General Administrative from 2010 to 2024
| LXRX Stock | USD 1.58 0.04 2.60% |
Selling General Administrative | First Reported 2000-03-31 | Previous Quarter 2.6 M | Current Value 32.6 M | Quarterly Volatility 5.9 M |
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many exotic indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0015 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
Lexicon | Selling General Administrative |
Latest Lexicon Pharmaceuticals' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Lexicon Pharmaceuticals over the last few years. It is Lexicon Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Lexicon Selling General Administrative Regression Statistics
| Arithmetic Mean | 41,576,671 | |
| Geometric Mean | 23,308,528 | |
| Coefficient Of Variation | 73.84 | |
| Mean Deviation | 24,956,734 | |
| Median | 32,342,000 | |
| Standard Deviation | 30,698,651 | |
| Sample Variance | 942.4T | |
| Range | 102.5M | |
| R-Value | 0.69 | |
| Mean Square Error | 538.4T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 4,703,324 | |
| Total Sum of Squares | 13193.7T |
Lexicon Selling General Administrative History
About Lexicon Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Lexicon Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Lexicon Pharmaceuticals investors use historical funamental indicators, such as Lexicon Pharmaceuticals's Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Lexicon Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Lexicon Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lexicon Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lexicon Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 97.7 M | 102.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lexicon Pharmaceuticals Correlation against competitors. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Lexicon Stock analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.80) | Revenue Per Share 0.005 | Quarterly Revenue Growth 24.071 | Return On Assets (0.51) |
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.